GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » EQL Pharma AB (OSTO:EQL) » Definitions » Cash Conversion Cycle

EQL Pharma AB (OSTO:EQL) Cash Conversion Cycle : 234.47 (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is EQL Pharma AB Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

EQL Pharma AB's Days Sales Outstanding for the three months ended in Sep. 2024 was 62.67.
EQL Pharma AB's Days Inventory for the three months ended in Sep. 2024 was 254.34.
EQL Pharma AB's Days Payable for the three months ended in Sep. 2024 was 82.54.
Therefore, EQL Pharma AB's Cash Conversion Cycle (CCC) for the three months ended in Sep. 2024 was 234.47.


EQL Pharma AB Cash Conversion Cycle Historical Data

The historical data trend for EQL Pharma AB's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EQL Pharma AB Cash Conversion Cycle Chart

EQL Pharma AB Annual Data
Trend Dec14 Dec15 Dec16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 177.93 95.32 53.41 138.09 188.08

EQL Pharma AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 209.77 205.61 173.59 209.32 234.47

Competitive Comparison of EQL Pharma AB's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EQL Pharma AB's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where EQL Pharma AB's Cash Conversion Cycle falls into.



EQL Pharma AB Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

EQL Pharma AB's Cash Conversion Cycle for the fiscal year that ended in Mar. 2024 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=76.02+209.27-97.21
=188.08

EQL Pharma AB's Cash Conversion Cycle for the quarter that ended in Sep. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=62.67+254.34-82.54
=234.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EQL Pharma AB  (OSTO:EQL) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


EQL Pharma AB Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of EQL Pharma AB's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


EQL Pharma AB Business Description

Comparable Companies
Traded in Other Exchanges
Address
Stortorget 1, 3rd Floor, Lund, SWE, 222 23
EQL Pharma AB is a pharmaceutical company engaged in developing and selling medicines to pharmacies and hospitals. The products offered by the company include generics and parallel imports. It operates and markets products to Nordic countries of Sweden, Denmark, Finland and Norway.

EQL Pharma AB Headlines

From GuruFocus